Journal article

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes

Mette Julsgaard, Christian L Hvas, Richard B Gearry, Peter R Gibson, Jan Fallingborg, Miles P Sparrow, Bo M Bibby, William R Connell, Steven J Brown, Michael A Kamm, Ian C Lawrance, Thea Vestergaard, Lise Svenningsen, Mille Baekdal, Heidi Kammerlander, Alissa Walsh, Trine Boysen, Peter Bampton, Graham Radford-Smith, Jens Kjeldsen Show all

INFLAMMATORY BOWEL DISEASES | OXFORD UNIV PRESS INC | Published : 2020

Abstract

BACKGROUND: Active inflammatory bowel disease (IBD) adversely affects pregnancy outcomes. Little is known about the risk of relapse after stopping anti-tumor necrosis factor (anti-TNF) treatment during pregnancy. We assessed the risk of relapse before delivery in women who discontinued anti-TNF treatment before gestational week (GW) 30, predictors of reduced infant birth weight, a marker associated with long-term adverse outcomes, and rates and satisfaction with counseling. METHODS: Pregnant women with IBD receiving anti-TNF treatment were prospectively invited to participate in an electronic questionnaire carried out in 22 hospitals in Denmark, Australia, and New Zealand from 2011 to 2015. ..

View full abstract